XENIOS AG, a commercial -stage medical device company, recently announced that it has received a significant cash infusion from existing investors. While the amount of investment was not disclosed, it was in the eight-figures range, led by ZFHN, which typically invests up to 10 million euros in any given transaction.
XENIOS is the recognized technology leader in minimally invasive medical devices that unite one console, XENIOS, with next-generation lung (novalung) and heart ( i -cor) therapies into a single platform for a market with revenue potential of nearly $9 billion.
“No other company except Xenios is offering minimally invasive disposable lung and heart therapies on oneplatform,” said Georg Matheis, MD, Managing Director of XENIOS. “The XENIOS platform provides fundamental advantages with its minimally invasive lung and heart therapies. Patients are awake and mobile. Self-determined patients facilitate improved outcomes. There is no ventilator-associated lung injury and pneumonia. Additionally, the XENIOS platform maintains a physiologic natural pulse designed to protect the heart.
Xenios AG
www.xenios-ag.com
